BOSTON, MA, USA I July 10, 2023 I Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors. TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration. The TNG462 phase 1/2 clinical trial will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in solid tumors with MTAP deletions.
“Dosing the first patient with our next-generation MTA-cooperative PRMT5 inhibitor, TNG462, demonstrates our deep commitment to developing transformative treatments for patients with MTAP-deleted cancers. MTAP deletions occur in 10-15 percent of solid tumors, including many with limited treatment options, and there currently are no FDA-approved treatments specifically for cancers with MTAP deletion,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “TNG908, our brain-penetrant MTA-cooperative PRMT5 inhibitor, also is being evaluated in an ongoing phase 1/2 study. Each molecule has unique properties, and by advancing both programs, we have the opportunity to make a difference in a broader range of indications.”
TNG908 and TNG462 are potent PRMT5 inhibitors that are selective for cancer cells with MTAP deletion. MTAP deletion causes accumulation of intracellular MTA, an inhibitory PRMT5 co-factor. TNG462 selectively binds to and inhibits PRMT5 in the presence of MTA, thus is selectively cytotoxic for cancer cells with MTAP deletion while sparing normal cells. In preclinical studies, both TNG462 and TNG908 induced deep tumor regressions in preclinical models of multiple cancer types.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
SOURCE: Tango Therapeutics
Post Views: 193
BOSTON, MA, USA I July 10, 2023 I Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients with MTAP-deleted solid tumors. TNG462 is a potentially best-in-class MTA-cooperative PRMT5 inhibitor previously granted Fast Track designation by the U.S. Food and Drug Administration. The TNG462 phase 1/2 clinical trial will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in solid tumors with MTAP deletions.
“Dosing the first patient with our next-generation MTA-cooperative PRMT5 inhibitor, TNG462, demonstrates our deep commitment to developing transformative treatments for patients with MTAP-deleted cancers. MTAP deletions occur in 10-15 percent of solid tumors, including many with limited treatment options, and there currently are no FDA-approved treatments specifically for cancers with MTAP deletion,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “TNG908, our brain-penetrant MTA-cooperative PRMT5 inhibitor, also is being evaluated in an ongoing phase 1/2 study. Each molecule has unique properties, and by advancing both programs, we have the opportunity to make a difference in a broader range of indications.”
TNG908 and TNG462 are potent PRMT5 inhibitors that are selective for cancer cells with MTAP deletion. MTAP deletion causes accumulation of intracellular MTA, an inhibitory PRMT5 co-factor. TNG462 selectively binds to and inhibits PRMT5 in the presence of MTA, thus is selectively cytotoxic for cancer cells with MTAP deletion while sparing normal cells. In preclinical studies, both TNG462 and TNG908 induced deep tumor regressions in preclinical models of multiple cancer types.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.
SOURCE: Tango Therapeutics
Post Views: 193
